about
Virus-like particles derived from Pichia pastoris-expressed dengue virus type 1 glycoprotein elicit homotypic virus-neutralizing envelope domain III-directed antibodiesRecombinant multiepitope protein for early detection of dengue infections.Replication-Defective Adenoviral Vaccine Vector for the Induction of Immune Responses to Dengue Virus Type 2Cissampelos pareira Linn: Natural Source of Potent Antiviral Activity against All Four Dengue Virus Serotypesp300/cAMP-responsive element-binding protein interactions with ets-1 and ets-2 in the transcriptional activation of the human stromelysin promoterRecombinant Dengue Virus 4 Envelope Glycoprotein Virus-Like Particles Derived from Pichia pastoris are Capable of Eliciting Homotypic Domain III-Directed Neutralizing Antibodies.Abrogation of a mitotic checkpoint by E2 proteins from oncogenic human papillomaviruses correlates with increased turnover of the p53 tumor suppressor protein.Dengue vaccines: state of the art.Pichia pastoris-expressed dengue 2 envelope forms virus-like particles without pre-membrane protein and induces high titer neutralizing antibodies.A small molecule inhibitor of dengue virus type 2 protease inhibits the replication of all four dengue virus serotypes in cell culture.Dengue: recent advances in biology and current status of translational research.Drugs for dengue: a patent review (2010-2014).Diagnostic potential and antigenic properties of recombinant tick-borne encephalitis virus subviral particles expressed in mammalian cells from Semliki Forest virus replicons.Investigational drugs in early development for treating dengue infection.Inexpensive designer antigen for anti-HIV antibody detection with high sensitivity and specificity.The prevalence of antibodies to adenovirus serotype 5 in an adult Indian population and implications for adenovirus vector vaccines.Electrospun manganese (III) oxide nanofiber based electrochemical DNA-nanobiosensor for zeptomolar detection of dengue consensus primer.Pichia pastoris-expressed dengue 3 envelope-based virus-like particles elicit predominantly domain III-focused high titer neutralizing antibodies.Virus-like particles displaying envelope domain III of dengue virus type 2 induce virus-specific antibody response in mice.Chimeric Hepatitis B core antigen virus-like particles displaying the envelope domain III of dengue virus type 2.Expression, purification and characterization of in vivo biotinylated dengue virus envelope domain III based tetravalent antigen.Pichia pastoris-expressed dengue virus type 2 envelope domain III elicits virus-neutralizing antibodies.Induction of neutralizing antibodies and T cell responses by dengue virus type 2 envelope domain III encoded by plasmid and adenoviral vectors.A synthetic dengue virus antigen elicits enhanced antibody titers when linked to, but not mixed with, Mycobacterium tuberculosis HSP70 domain II.The identification of immunodominant linear epitopes of dengue type 2 virus capsid and NS4a proteins using pin-bound peptides.Recombinant dengue virus type 2 envelope/hepatitis B surface antigen hybrid protein expressed in Pichia pastoris can function as a bivalent immunogen.Application of simple fed-batch technique to high-level secretory production of insulin precursor using Pichia pastoris with subsequent purification and conversion to human insulinSimultaneous detection of Human Immunodeficiency Virus 1 and Hepatitis B virus infections using a dual-label time-resolved fluorometric assay.Major antifungal activity from the bulbs of Indian squill Urginea indica is a chitinase.Expression of hepatitis B surface antigen in the methylotrophic yeast Pichia pastoris using the GAP promoter.A tetravalent virus-like particle vaccine designed to display domain III of dengue envelope proteins induces multi-serotype neutralizing antibodies in mice and macaques which confer protection against antibody dependent enhancement in AG129 mice.Pichia pastoris-Expressed Bivalent Virus-Like Particulate Vaccine Induces Domain III-Focused Bivalent Neutralizing Antibodies without Antibody-Dependent Enhancement in Vivo.A quinoline compound inhibits the replication of dengue virus serotypes 1-4 in Vero cells.A highly sensitive and specific time resolved fluorometric bridge assay for antibodies to HIV-1 and -2.Dengue envelope-based 'four-in-one' virus-like particles produced using Pichia pastoris induce enhancement-lacking, domain III-directed tetravalent neutralising antibodies in mice.Effect of copy number on the expression levels of hepatitis B surface antigen in the methylotrophic yeast Pichia pastorisAffinity purification of recombinant interferon-alpha on a mimetic ligand adsorbentNext generation designer virus-like particle vaccines for dengueDengue vaccine development: Global and Indian scenariosPichia pastoris-expressed Zika virus envelope domain III on a virus-like particle platform: design, production and immunological evaluation
P50
Q26314715-ACACC4A2-D38A-44BD-A5A3-04AEC63C89A9Q27472835-D579DA89-258F-411B-AB78-2FE9D44B71DFQ27487570-E0E4F15E-6586-4645-AF2D-785B1754685BQ28551786-8BE3372E-A789-4EA9-9E3C-48DFB8538F3DQ28610029-4AAFBD61-188A-4738-8C0A-193D22DF249AQ30395028-77ED65E0-E862-47E0-AF6E-8DFE454B6C34Q33886001-53D7FE0C-1845-43C4-9C21-751474DFE147Q34109652-7E18F7C8-ECA5-4382-B163-6B1248941288Q34746139-5884103B-D54F-46C0-8062-D673F91E1BA4Q35082478-7990212B-0DE0-475B-BE5D-DCA2B6B29F7CQ37411387-88DB3755-0CBB-424B-9112-76BFD4BA0CCCQ38256785-1F8B9C00-96A3-4D0D-B6A0-1874027FC868Q38322970-94E37D5A-C67B-4177-99F4-BA641CCDC9CEQ38870485-B65C627F-6DFC-4E0B-AE1C-5388A593036FQ39605470-68929935-B291-453C-9C09-9272A272E5BDQ39750086-A8B7E0E5-79FD-4F61-BE9E-7DA3AACFD4ECQ40077083-3AFA206E-C2A2-4A20-BB36-AC129A818A6DQ40136145-762E9BE8-81BB-411C-9A2D-68A23F62839EQ40263422-C9FFCD82-D20E-4303-A036-C7C0C7928B5DQ40280642-4A866FF9-38C5-4628-B758-6A6257F3F6C5Q40359814-AAAEE2D5-7CD1-4FAE-BAA8-F959259B3F46Q40364336-A6D1CBCF-3265-46A0-ACEB-6F57A9FF0459Q40474022-2E73780A-91B9-4F8B-BBC7-4E106FE637F2Q40481109-090A33FB-5381-40B4-9782-A46268B69B07Q40503592-C1E9A851-361F-4B9B-BE89-8349DDADBEC5Q40574332-46EC7C3A-2E4C-4CE3-A9C4-80D3F3A89544Q40935650-9CBBE76B-7716-4E6C-93B9-2FF32AD5C689Q41148246-EBE3A851-9F53-4CDB-A433-1D4C5F129DF9Q42687105-D434A35A-BB94-45A8-9B10-6F326051F1E7Q43620998-FEE82C4F-B88F-40EE-9EC8-1CE61FB3BFB0Q47194469-6A1101BD-2180-4486-ADA2-6299A2E0A76FQ47549097-FF711FD9-1EB5-45D7-BD37-841ECDA6A956Q51336005-96139593-47E4-47FB-BB54-BB350EFD6138Q54372195-D6F02BD7-C1A4-481C-9308-4ADFFD45B22BQ55244392-DCAAD1DD-D292-47B6-8113-B07E447E9D2CQ73404791-F8C296DF-B78E-48D5-9D49-EC90C29733BFQ74525352-DC27CDCB-5FE8-43B2-B50E-DE2CFD9CC12EQ90761568-16E9F882-9B8B-467D-9985-BA19B92B8B1DQ91234260-A6F1AF7F-6709-4F2B-A451-B91632A4AC6FQ92058721-52D6D8D1-A5D2-43E4-A220-4B25DC96D749
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Sathyamangalam Swaminathan
@ast
Sathyamangalam Swaminathan
@en
Sathyamangalam Swaminathan
@es
Sathyamangalam Swaminathan
@nl
Sathyamangalam Swaminathan
@sl
type
label
Sathyamangalam Swaminathan
@ast
Sathyamangalam Swaminathan
@en
Sathyamangalam Swaminathan
@es
Sathyamangalam Swaminathan
@nl
Sathyamangalam Swaminathan
@sl
prefLabel
Sathyamangalam Swaminathan
@ast
Sathyamangalam Swaminathan
@en
Sathyamangalam Swaminathan
@es
Sathyamangalam Swaminathan
@nl
Sathyamangalam Swaminathan
@sl
P106
P1153
7102380774
P31
P496
0000-0002-4388-2248